Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer

Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA
New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )
3 Jun 2019

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations

Dr Hedy Kindler - University of Chicago, Chicago, USA
PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations ( Dr Hedy Kindler - University of Chicago, Chicago, USA )
2 Jun 2019

Enzalutamide as treatment for men with mHSPC who have received testosterone suppression

Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA
Enzalutamide as treatment for men with mHSPC who have received testosterone suppression ( Dr Christopher Sweeney -  Dana-Farber Cancer Institute, Boston, USA )
2 Jun 2019

Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroids improving quality of life

Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, USA
Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroids improving quality of life ( Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, USA )
2 Jun 2019

Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer

Dr Hedy Kindler - University of Chicago, Chicago, USA
Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer ( Dr Hedy Kindler - University of Chicago, Chicago, USA )
2 Jun 2019

Comment: It is essential to identify the BRCA gene in pancreatic cancer patients allowing them to be treated with an oral agent

Dr Suzanne Cole - UT Southwestern Medical Center, Dallas, USA
Comment: It is essential to identify the BRCA gene in pancreatic cancer patients allowing them to be treated with an oral agent ( Dr Suzanne Cole - UT Southwestern Medical Center, Dallas, USA )
2 Jun 2019

AXL inhibitor bemcentinib in combination with chemotherapy exerts anti-leukaemic activity in AML patients

Dr Sonja Loges - University Hospital Eppendorf, Hamburg, Germany
AXL inhibitor bemcentinib in combination with chemotherapy exerts anti-leukaemic activity in AML patients ( Dr Sonja Loges - University Hospital Eppendorf, Hamburg, Germany )
1 Jun 2019

PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer

Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
1 Jun 2019

Subcutaneous versus intravenous daratumumab administration in patients with relapsed or refractory multiple myeloma

Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain
Subcutaneous versus intravenous daratumumab administration in patients with relapsed or refractory multiple myeloma ( Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain )
1 Jun 2019

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer

Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
1 Jun 2019

Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer

Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
1 Jun 2019

Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA
Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2019